Ikaria, Inc. announced today that Dr. Flemming Ornskov has been named President and Chief Executive Officer of the Seattle biotechnology company. He was also named a member of Ikaria’s board of directors. “Dr. Ornskov’s pharmaceutical expertise and his blend of clinical and entrepreneurial skills make him an ideal choice as leader of our company,” said Vaughn Kailian, chairman of the Ikaria board of directors. “Under his leadership Ikaria will commercialize metabolic control products, which should benefit critically ill patients worldwide and provide a new paradigm in critical care medicine.”
